녹내장 : 7개 시장 의약품 예측과 시장 분석 - 업데이트

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Glaucoma market through 2033.

According to GlobalData, 2023 sales of glaucoma therapeutics across the 7MM are estimated to be $2.1 billion. The market is projected to grow at a compound annual growth rate (CAGR) of 2.1%, reaching approximately $2.5 billion by 2033.

The major drivers of glaucoma market growth over the forecast period are -

• A projected increase in the prevalence of glaucoma throughout the 7MM resulting from an aging population.
• The launches of six pipeline agents in the US and Japan.
• The anticipated launches of new products are expected to address unmet needs in the treatment of glaucoma.

These are the major barriers that will restrict the growth of the CKD market during the forecast period -

• Several products are due to lose exclusivity within the forecast period, and the subsequent generic erosion represents a significant impediment to growth.
• Poor adherence to therapy will continue to stymie the sales of topical glaucoma therapies throughout the forecast period.
• The crowded and highly genericized nature of the glaucoma market represents significant competition for new therapies.

Scope

• Overview of glaucoma, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized glaucoma therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the glaucoma therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for glaucoma treatment. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the global glaucoma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 7MM glaucoma therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM glaucoma therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

• About GlobalData

1 Glaucoma: Executive Summary

• 1.1 The glaucoma market will increase between 2023 and 2033.
• 1.2 The development of drugs with novel MOAs or routes of administration marks a shift in glaucoma corporate strategy.
• 1.3 Unmet needs remain for glaucoma, particularly improving patient compliance.
• 1.4 Late-stage pipeline drugs entering the glaucoma market are poised to drive growth.
• 1.5 What do physicians think?

2 Introduction

• 2.1 Catalyst
• 2.2 Related reports
• 2.3 Upcoming reports

3 Disease Overview

• 3.1 Etiology and pathophysiology
  • 3.1.1 Overview
  • 3.1.2 Etiology
  • 3.1.3 NTG
  • 3.1.4 Pathophysiology
• 3.2 Classification or staging systems

4 Epidemiology

• 4.1 Disease background
• 4.2 Risk factors and comorbidities.
• 4.3 Global and historical trends
• 4.4 7MM forecast methodology
  • 4.4.1 Sources
  • 4.4.2 Forecast assumptions and methods
  • 4.4.3 Forecast assumptions and methods: diagnosed prevalent cases of POAG (excluding NTG)
  • 4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of NTG.
  • 4.4.5 Forecast assumptions and methods: diagnosed prevalent cases of PACG
  • 4.4.6 Forecast assumptions and methods: diagnosed incident cases of acute PACG.
  • 4.4.7 Forecast assumptions and methods: diagnosed prevalent cases of secondary glaucoma.
• 4.5 Epidemiological forecast for glaucoma (2023-33)
  • 4.5.1 Diagnosed prevalent cases of POAG (excluding NTG)
  • 4.5.2 Age-specific diagnosed prevalent cases of POAG (excluding NTG)
  • 4.5.3 Sex-specific diagnosed prevalent cases of POAG (excluding NTG)
  • 4.5.4 Diagnosed prevalent cases of NTG
  • 4.5.5 Diagnosed prevalent cases of PACG.
  • 4.5.6 Age-specific diagnosed prevalent cases of PACG
  • 4.5.7 Sex-specific diagnosed prevalent cases of PACG
  • 4.5.8 Diagnosed prevalent cases acute and chronic PACG
  • 4.5.9 Diagnosed incident cases of acute PACG
  • 4.5.10 Diagnosed incident cases of secondary glaucoma
• 4.6 Discussion
  • 4.6.1 Epidemiological forecast insight
  • 4.6.2 COVID-19 impact.
  • 4.6.3 Limitations of the analysis
  • 4.6.4 Strengths of the analysis

5 Disease Management

• 5.1 Diagnosis overview
  • 5.1.1 Ophthalmoscopy
  • 5.1.2 Tonometry
  • 5.1.3 Perimetry
  • 5.1.4 Pachymetry
  • 5.1.5 Gonioscopy
• 5.2 Treatment overview
  • 5.2.1 Treatment guidelines
• 5.3 KOL insights on disease management

6 Current Treatment Options

• 6.1 Overview

7 Unmet Needs and Opportunity Assessment

• 7.1 Overview
• 7.2 Improved patient compliance
• 7.3 Treatments with better IOP lowering-ability
• 7.4 Novel drug delivery systems
• 7.5 Neuroprotective drugs
• 7.6 Improved diagnosis and monitoring

8 R&D Strategies

• 8.1 Overview
  • 8.1.1 New IOP-lowering drugs
  • 8.1.2 Implants in glaucoma
• 8.2 Clinical trials design
  • 8.2.1 Clinical endpoints for glaucoma
  • 8.2.2 Inclusion and exclusion criteria

9 Pipeline Assessment

• 9.1 Overview
• 9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

• 10.1 Overview
• 10.2 Competitive assessment

11 Current and Future Players

• 11.1 Overview
• 11.2 Deal-making trends

12 Market Outlook

• 12.1 Global markets
  • 12.1.1 Forecast
  • 12.1.2 Drivers and barriers - global (7MM) issues
• 12.2 US
  • 12.2.1 Forecast
  • 12.2.2 Key events
  • 12.2.3 Drivers and barriers
• 12.3 5EU
  • 12.3.1 Forecast
  • 12.3.2 Key events
  • 12.3.3 Drivers and barriers
• 12.4 Japan
  • 12.4.1 Forecast
  • 12.4.2 Key events
  • 12.4.3 Drivers and barriers

13 Appendix

• 13.1 Bibliography
• 13.2 Abbreviations
• 13.3 Methodology
  • 13.3.1 Forecasting methodology
• 13.4 Primary research - KOLs interviewed for this report.
  • 13.4.1 KOLs
• 13.5 Primary research - prescriber survey
• 13.6 About the authors
  • 13.6.1 Analyst
  • 13.6.2 Therapy Area Director
  • 13.6.3 Epidemiologist
  • 13.6.4 Reviewers, epidemiology
  • 13.6.5 Vice President of Disease Intelligence and Epidemiology
  • 13.6.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence
• Contact Us